MAPT and Alzheimer disease: In the 24-week trial, the patients received 2–4 g/d or placebo to determine effects in cognition test (ADAS-Cog and MMSE), executive function (ADCS-ADL), and AD biomarkers (plasma Aβ, tau, and isoprostanes).